ABOVE: A patient cell infected with SARS-CoV-2
FLICKR, NIAID
Serum samples from 20 individuals who received the Pfizer-BioNTech vaccine against SARS-CoV-2 thwarted a version of the coronavirus with the so-called N501Y mutation, according to a preprint posted to bioRxiv yesterday (January 7). This mutation is one of many sequence changes present in the B.1.1.7 and 501.V2 variants of SARS-CoV-2 that were first detected in the UK and South Africa, respectively, and are now rapidly spreading around the world.
“There’s no reason to think the vaccines won’t work just as well on these strains,” Frederic Bushman of the University of Pennsylvania who tracks how the virus mutates and was not involved in the work, tells the Associated Press. But he adds that the study only examined one mutation and the B.1.1.7 and 501.V2 variants have many more mutations that were not tested.
N501Y resides within the coronavirus’s spike protein that enables entry ...